BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 36011286)

  • 1. miR-23b-3p Modulating Cytoprotective Autophagy and Glutamine Addiction in Sorafenib Resistant HepG2, a Hepatocellular Carcinoma Cell Line.
    Kaur R; Kanthaje S; Taneja S; Dhiman RK; Chakraborti A
    Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma.
    Jing Z; Ye X; Ma X; Hu X; Yang W; Shi J; Chen G; Gong L
    Cancer Med; 2020 Jun; 9(12):4324-4338. PubMed ID: 32324343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacterial metabolite butyrate in modulating sorafenib-targeted microRNAs to curtail its resistance in hepatocellular carcinoma.
    Kumar M; Kaur R; Kanthaje S; Dhiman RK; Chakraborti A
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):5823-5839. PubMed ID: 36583742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-375 attenuates sorafenib resistance of hepatocellular carcinoma cells by inhibiting cell autophagy.
    Wang D; Yang J
    Acta Biochim Pol; 2023 Apr; 70(2):239-246. PubMed ID: 37068178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription.
    Lin Z; Xia S; Liang Y; Ji L; Pan Y; Jiang S; Wan Z; Tao L; Chen J; Lin C; Liang X; Xu J; Cai X
    Theranostics; 2020; 10(19):8834-8850. PubMed ID: 32754282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PU.1/microRNA-142-3p targets ATG5/ATG16L1 to inactivate autophagy and sensitize hepatocellular carcinoma cells to sorafenib.
    Zhang K; Chen J; Zhou H; Chen Y; Zhi Y; Zhang B; Chen L; Chu X; Wang R; Zhang C
    Cell Death Dis; 2018 Feb; 9(3):312. PubMed ID: 29472524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiRNA-124-3p.1 sensitizes hepatocellular carcinoma cells to sorafenib by regulating FOXO3a by targeting AKT2 and SIRT1.
    Dong ZB; Wu HM; He YC; Huang ZT; Weng YH; Li H; Liang C; Yu WM; Chen W
    Cell Death Dis; 2022 Jan; 13(1):35. PubMed ID: 35013144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-138-1-3p sensitizes sorafenib to hepatocellular carcinoma by targeting PAK5 mediated β-catenin/ABCB1 signaling pathway.
    Li TT; Mou J; Pan YJ; Huo FC; Du WQ; Liang J; Wang Y; Zhang LS; Pei DS
    J Biomed Sci; 2021 Aug; 28(1):56. PubMed ID: 34340705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells.
    Li W; Dong X; He C; Tan G; Li Z; Zhai B; Feng J; Jiang X; Liu C; Jiang H; Sun X
    J Exp Clin Cancer Res; 2019 May; 38(1):183. PubMed ID: 31053148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma.
    Shao YY; Chen PS; Lin LI; Lee BS; Ling A; Cheng AL; Hsu C; Ou DL
    Br J Cancer; 2022 Jun; 126(12):1806-1814. PubMed ID: 35236936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The lncRNA lnc-TSI antagonizes sorafenib resistance in hepatocellular carcinoma via downregulating miR-4726-5p expression and upregulating KCNMA1 expression.
    Chen F; Jiang J; Liu D; Li H; Dong L; Song Y; Zhang Y; Wang J; Qin Y; Zhao G
    J Mol Histol; 2024 Feb; 55(1):83-96. PubMed ID: 38165571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exosomal MiR-744 Inhibits Proliferation and Sorafenib Chemoresistance in Hepatocellular Carcinoma by Targeting PAX2.
    Wang G; Zhao W; Wang H; Qiu G; Jiang Z; Wei G; Li X
    Med Sci Monit; 2019 Sep; 25():7209-7217. PubMed ID: 31553714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-128-3p overexpression sensitizes hepatocellular carcinoma cells to sorafenib induced apoptosis through regulating DJ-1.
    Guo XL; Wang HB; Yong JK; Zhong J; Li QH
    Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6667-6677. PubMed ID: 30402839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-200c-3p, miR-222-5p, and miR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.
    de la Cruz-Ojeda P; Schmid T; Boix L; Moreno M; Sapena V; Praena-Fernández JM; Castell FJ; Falcón-Pérez JM; Reig M; Brüne B; Gómez-Bravo MA; Giráldez Á; Bruix J; Ferrer MT; Muntané J
    Cells; 2022 Aug; 11(17):. PubMed ID: 36078082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-25 enhances autophagy and promotes sorafenib resistance of hepatocellular carcinoma via targeting FBXW7.
    Feng X; Zou B; Nan T; Zheng X; Zheng L; Lan J; Chen W; Yu J
    Int J Med Sci; 2022; 19(2):257-266. PubMed ID: 35165511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-23b-3p Plays an Oncogenic Role in Hepatocellular Carcinoma.
    Hayashi M; Yamada S; Kurimoto K; Tanabe H; Hirabayashi S; Sonohara F; Inokawa Y; Takami H; Kanda M; Tanaka C; Nakayama G; Koike M; Kodera Y
    Ann Surg Oncol; 2021 Jun; 28(6):3416-3426. PubMed ID: 33140250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-486-3p mediates hepatocellular carcinoma sorafenib resistance by targeting FGFR4 and EGFR.
    Ji L; Lin Z; Wan Z; Xia S; Jiang S; Cen D; Cai L; Xu J; Cai X
    Cell Death Dis; 2020 Apr; 11(4):250. PubMed ID: 32313144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma.
    Lai HH; Li CW; Hong CC; Sun HY; Chiu CF; Ou DL; Chen PS
    Mol Oncol; 2019 Apr; 13(4):928-945. PubMed ID: 30657254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma.
    Lu Y; Chan YT; Tan HY; Zhang C; Guo W; Xu Y; Sharma R; Chen ZS; Zheng YC; Wang N; Feng Y
    J Exp Clin Cancer Res; 2022 Jan; 41(1):3. PubMed ID: 34980204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.